Literature DB >> 6643704

Thioridazine effect on desipramine plasma levels.

J Hirschowitz, J A Bennett, F P Zemlan, D L Garver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6643704

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

1.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of clomipramine.

Authors:  A E Balant-Gorgia; M Gex-Fabry; L P Balant
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Combined thioridazine and desipramine: early antidepressant response.

Authors:  J A Bennett; J Hirschowitz; F Zemlan; D N Thurman; D L Garver
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; P Dayer; J M Aeschlimann; G Garrone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

6.  Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.

Authors:  K Brøsen; J G Hansen; K K Nielsen; S H Sindrup; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.